Reiterates 2025 Outlook for Consolidated Revenue and Adjusted EBITDA Strengthened Balance Sheet and Extended Maturity Profile Through Recent Financings Net Income of $1.609 Billion for the Third Quarter Includes One-Time Gain Related to Merger with WindstreamConsolidated Revenue and Adjusted EBITDA of $722.6 Million and $327.8 Million, Respectively, for the Third Quarter ____________________________ LITTLE ROCK, Ark., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNI ...

公司财务表现 - 公司持有2,106,989枚SOL，较2025年9月10日的2,018,419枚增长4.4% [6] - 以2025年10月31日每枚SOL 188.56美元计算，SOL资产总价值为3.97亿美元 [6] - 公司SOL持仓的未实现收益为7200万美元，其中包括价格升值、质押奖励和锁仓SOL折扣 [1][6][7] - 经调整的每股SOL持有量为0.0187枚，以SOL数量计自策略启动以来增长47%，以美元价值（3.52美元）计增长82% [1][6][8] - 2025年4月公司完成1亿美元股权私募融资，发行价为2.28美元，截至2025年10月31日，投资者获得96%的投资回报，同期SOL价格涨幅为24%，公司股票表现超出72个百分点 [9] 公司运营策略 - 公司几乎所有SOL资产均用于质押，年化收益率约为7-8%，当前每日质押收入约为7.5万美元 [6] - 投资组合中约42%为锁仓SOL，购买时较现货价格有百分之十几的折扣，为股东提供了内置收益 [6] - 公司致力于通过智能资本发行、质押和折价购买锁仓代币这三种关键的价值累积机制为股东创造长期增量价值 [2][13] - 公司定位为专注于Solana的数字资产国库公司，旨在以纪律性和增值的方式持有尽可能多的SOL [13] 公司市场活动与治理 - 公司咨询委员会新增了SOL爱好者S◎L Big Brain和期权专家Jon Najarian [6] - 公司参与了FT Partners金融科技大会2025、A.G.P.数字资产国库展示会和Maxim增长峰会 [6] - REXShares和Tuttle Capital推出了T-REX 2X Long UPXI Daily Target ETF (PXIU) [6] - 公司首席执行官强调，尽管市场对国库公司的情绪减弱，公司仍处于增长态势 [2] - 公司首席战略官指出，其优势在于以Solana这一终极赢家资产为基础，并专注于创新、资本市场专业知识和风险审慎策略 [2]

Medidata Patient Experience will accelerate CTI’s treatments for patients with oncology, metabolic, cardiovascular, central nervous system, and immune conditionsNEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and CTI Clinical Trial and Consulting (CTI), a global leader in research services for advanced therapies, have expanded their 12-year relationship. The new agreement places the Medidata Patie ...

New NIH grant awards $2.5 million over 5 years for mechanistic studyBURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded a new grant – totaling approximately $2.5 million over five years – to a research team led by Principal Investigator Dr. Claudia Padu ...

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Captivision Inc. (“Captivision” or the “Company”) (NASDAQ: CAPT), a pioneering manufacturer and global LED solution provider, announced that it has been informed that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to extend the deadline for regaining compliance with the Listing Rules of The Nasdaq Stock Market (“Nasdaq”), subject to certain conditions related to the Company’s ongoing efforts to regain compliance with Nasdaq Listing Rule 525 ...

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET. To access the public webcast of the event, please visit the Events and ...

公司近期活动 - 公司将参加Guggenheim第二届年度医疗健康创新大会，并进行炉边谈话，时间为2025年11月11日下午1:30 [1][4] - 公司将参加Stifel 2025医疗健康大会，并进行演讲，时间为2025年11月12日下午2:00 [1][4] - 相关活动的网络直播回放将在公司网站上存档90天 [1] 公司业务与研发管线 - 公司是一家后期生物制药公司，致力于为免疫介导性疾病患者开发新一代靶向疗法 [2] - 公司利用其专有数据分析平台和精准医疗方法，正在开发一系列口服酪氨酸激酶2抑制剂管线 [2] - 主要候选药物envudeucitinib用于治疗中重度斑块状银屑病和系统性红斑狼疮等系统性免疫介导疾病 [2] - 候选药物A-005用于治疗神经炎症和神经退行性疾病 [2] - 管线还包括lonigutamab，一种用于治疗甲状腺眼病的皮下注射抗胰岛素样生长因子1受体疗法 [2] - 公司还拥有多个通过其精准方法识别的临床前项目 [2]

Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual MeetingPreliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rateUpdated preliminary data from the ongoing Phase Ib FRIDA trial evaluating iadademstat in combination with gilteritinib in FLT3-mutated relapsed/refractory AML showed a 67% response rate in the expanded dose, superior to both histori ...

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Private Bancorp of America, Inc. (OTCQX:PBAM), (“Company”) and CalPrivate Bank (“Bank”) are proud to announce the grand opening of CalPrivate Bank’s newest regional branch offices in Montecito serving California’s Central Coast. This new location expands the Bank’s commitment to delivering our trademark Distinctively Different® personalized banking services and strengthening community relationships across the region. The full-service office, located at 148 ...

GREENWICH, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQG) (NasdaqGS: OXSQH) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended September 30, 2025. On October 30, 2025, our Board of Directors declared the following distributions on our common stock: Month EndingRecord DatePayment DateAmount Per ShareJanuary 31, 2026January 16, 2026January 30, 2026$0.035February 28, 2026February 13, 2 ...